GILEAD SCIENCES, INC. - 8-K Filing
Gilead Sciences reports Q3 2026 product sales of $8.3 billion, a 13% increase YoY driven by HIV and oncology growth. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $GILD
Read the full article at SEC EDGAR
Part of the story Cloudflare Shares Surge Following Strong Q3 Results and Raised Full-Year Guidance (85 articles)